Search

Displaying results 3341 - 3350 of 8196 in total
  1. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  2. Drug

    Perflubutane

    go.drugbank.com/drugs/DB12821
    ApprovedInvestigationalWithdrawn

    Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable ultrasound to compete more e...

  3. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. Similar to the previously developed tafamidis, acoramidis is used to stabilize TTR in its tetrameric form, preventing the formatio...

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Ascorbyl phosphate

    go.drugbank.com/drugs/DB11352
    ApprovedInvestigational

    As vitamin C is susceptible to breakdown of compound and discoloration in cosmetic formulations, ascorbyl phosphate, along with other Vitamin C derivatives, acts as an active and stable precursor of vitamin … While ascorbyl phosphate salts provide a constant delivery of vitamin C into the skin, they also mediate an antioxidant action to act as a free radical scavenger and increases collagen production *in vitro

  5. Drug

    Goserelin

    go.drugbank.com/drugs/DB00014
    ApprovedInvestigational

    Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the...

  6. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

  7. Drug

    Benziodarone

    go.drugbank.com/drugs/DB13277
    ApprovedWithdrawn

    It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].

  8. Drug

    Cytarabine

    go.drugbank.com/drugs/DB00987
    ApprovedInvestigational

    Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 1-beta-D-Arabinofuranosylcytosine, cytosine-β-D-arabinofuranoside
  9. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin, 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin
  10. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers